| Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial E Ramacciotti, LB Agati, D Calderaro, VCR Aguiar, AC Spyropoulos, ... The Lancet 399 (10319), 50-59, 2022 | 265 | 2022 |
| Zika and Chikungunya virus and risk for venous thromboembolism E Ramacciotti, LB Agati, VCR Aguiar, N Wolosker, JC Guerra, ... Clinical and Applied Thrombosis/Hemostasis 25, 1076029618821184, 2019 | 64 | 2019 |
| Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: rationale and design of the MICHELLE trial E Ramacciotti, LB Agati, D Calderaro, GG Volpiani, CCC de Oliveira, ... American heart journal 242, 115-122, 2021 | 23 | 2021 |
| Rationale and design for the study Apixaban versus ClopidoGRel on a background of aspirin in patient undergoing InfraPoPliteal angioplasty for critical limb ischemia: AGRIPPA trial RB Biagioni, RD Lopes, LB Agati, R Sacilotto, N Wolosker, ML Sobreira, ... American Heart Journal 227, 100-106, 2020 | 19 | 2020 |
| Rivaroxaban versus enoxaparin for thromboprophylaxis after major gynecological cancer surgery: the VALERIA trial: V enous thromboembolism prophyl A xis after gyneco L ogical p … ALM Longo de Oliveira, RF de Oliveira Pereira, LB Agati, CM Ribeiro, ... Clinical and Applied Thrombosis/Hemostasis 28, 10760296221132556, 2022 | 18 | 2022 |
| Effects of physical training on the mechanical resistance of rat femur proximal thirds AF Aguiar, LB Agati, SS Müller, OC Pereira, M Dal-Pai-Silva Acta Ortopedica Brasileira 18, 245-249, 2010 | 17 | 2010 |
| Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care in the treatment of patients hospitalized with moderate-to-critical COVID-19 … LP Bonifácio, E Ramacciotti, LB Agati, FC Vilar, ACT Silva, ... Revista da Sociedade Brasileira de Medicina Tropical 56, e0565-2022, 2023 | 5 | 2023 |
| Direct oral anticoagulants and cancer-associated thrombosis management. Where do we stand in 2019? E Ramacciotti, LB Agati, RA Caffaro, GG Volpiani, RD Lopes, ... Clinical and Applied Thrombosis/Hemostasis 25, 1076029619856433, 2019 | 5 | 2019 |
| Efficacy and safety of a biosimilar versus branded enoxaparin in the prevention of venous thromboembolism following major abdominal surgery: a randomized, prospective, single … E Ramacciotti, U Ferreira, AJV Costa, SRO Raymundo, JA Correa, ... Clinical and Applied Thrombosis/Hemostasis 24 (8), 1208-1215, 2018 | 5 | 2018 |
| Efeitos do treinamento físico sobre a resistência mecânica do terço proximal do fêmur de ratos AF Aguiar, LB Agati, SS Müller, OC Pereira, M Dal-Pai-Silva Acta Ortopédica Brasileira 18, 245-249, 2010 | 5 | 2010 |
| Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial E Ramacciotti, LB Agati, GG Volpiani, KF Brito, CM Ribeiro, VCR Aguiar, ... Clinical and Applied Thrombosis/Hemostasis 28, 10760296211073922, 2022 | 3 | 2022 |
| Comparative studies on the anticoagulant profile of branded enoxaparin and a new biosimilar version D Qneibi, E Ramacciotti, AS Macedo, RA Caffaro, LB Agati, F Siddiqui, ... Clinical and Applied Thrombosis/Hemostasis 26, 1076029620960820, 2020 | 3 | 2020 |
| Effects of nandrolone decanoate and resistance exercise on skeletal muscle in adult male rats C Dela Cruz, LB Agati, O Pereira International Journal of Morphology, 613-620, 2012 | 3 | 2012 |
| Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic … CCC de Oliveira, LB Agati, CM Ribeiro, VCR Aguiar, RA Caffaro, ... The Lancet Regional Health–Americas 24, 2023 | 2 | 2023 |
| Rivaroxaban for patients with intermittent claudication E Ramacciotti, GG Volpiani, KF Britto, LB Agati, CM Ribeiro, VCR Aguiar, ... NEJM evidence 3 (9), EVIDoa2400021, 2024 | 1 | 2024 |
| Efficacy and safety of Ixekizumab vs. low-dose IL-2 vs. Colchicine vs. standard of care on the treatment of patients hospitalized with moderate to critical COVID-19: a pilot … L Pimenta Bonifácio, E Ramacciotti, LB Agati, FC Vilar, AC Tojal da Silva, ... | 1 | 2022 |
| Cost-effectiveness analysis of extended thromboprophylaxis with rivaroxaban versus no prophylaxis in high-risk patients after hospitalisation for COVID-19: an economic … CCC Oliveira, LB Agati, CM Ribeiro, VCR Aguiar, RA Caffaro, MS Santos, ... The Lancet, 2023 | | 2023 |
| Efficacy of ixekizumab vs. IL-2 vs. colchicine vs. standard of care for the treatment of hospitalized patients with COVID-19: preliminary results of a randomized clinical trial … L Bonifacio, E Ramacciotti, L Agati, F Vilar, A Tojal, H Souza, ... Antimicrobial Resistance & Infection Control 10, 61, 2021 | | 2021 |
| Transcranial Direct Current Stimulation and EEG-Alpha power in elderly undergoing elective on-pump CABG: Design of a pilot exploratory proof-of-concept trial SK Medorima, AS Chávez, AR Negrín, B de Souza Paolino, ... Principles and Practice of Clinical Research 2 (2), 2016 | | 2016 |
| Efectos del Decanoato de Nandrolona y el Ejercicio de Resistencia en el Músculo Esquelético de Ratas Machos Adultos C Dela Cruz, LB Agati, O Pereira International Journal of Morphology 30 (2), 613-620, 2012 | | 2012 |
